SAT-120-Influence of previous acute decompensation and organ failure on the long-term prognosis in cirrhotic patients with decompensation

2019 ◽  
Vol 70 (1) ◽  
pp. e683
Author(s):  
Do Seon Song ◽  
Tae Yeob Kim ◽  
Eileen L Yoon ◽  
Jin Mo Yang ◽  
Hee Yeon Kim ◽  
...  
2019 ◽  
Vol 8 (10) ◽  
pp. 1600
Author(s):  
Yoon ◽  
Kim ◽  
Song ◽  
Kim ◽  
Kim ◽  
...  

Recurrent episodes of liver injury may either waste hepatic reserve or induce tolerance to further injury. We aimed to investigate whether the previous acute decompensation (AD) in liver cirrhosis (LC) affects the long-term transplant-free survival of patients with alcoholic hepatitis (AH). The survival data of 894 alcoholic LC cohort who had been admitted with acute deterioration in 21 academic hospitals in Korea were prospectively followed up. Enrolled patients were divided into three groups: Group one, without AH; group two, with nonsevere AH; and group three, with severe AH. Although the baseline liver function was not different between the groups with or without previous AD, it was a significant predictor of poor long-term outcomes. The presence of previous AD negatively affected long-term overall survival (HR 1.62, 95% C.I. 1.20–2.18, p = 0.002) in groups one and two as a whole, independent of the Model for End-stage Liver Disease score. The three-month conditional survival was significantly worse in group three for up to 12 months in the presence of previous AD (p < 0.05). We concluded that not only the severity of AH, but also the prior AD is an important predictor of long-term outcomes in alcoholic LC patients with acute deterioration.


2021 ◽  
Author(s):  
Lu Wang ◽  
Wenxiong Xu ◽  
Xuejun Li ◽  
Dabiao Chen ◽  
Yeqiong Zhang ◽  
...  

Abstract Introduction and Objectives: The long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) is not well characterized. We sought to assess the short-term and long-term outcomes and the associated risk factors of HBV-ACLF patients in south China.Patients and Methods: We retrospectively analyzed clinical data, adverse events, and clinical endpoint events of HBV-ACLF patients treated at our department between January 2014 and December 2018. Results: A total of 1177 HBV-ACLF patients were included in the study, including 616 (52.3%) cirrhotic patients and 561 (47.7%) non-cirrhotic patients. 973 (83%) patients were associated only with HBV, and 204 (17%) patients had two or more etiologies. The leading cause of simple HBV-ACLF patients was lack of antiviral treatment and the proportion of patients receiving antiviral treatment for HBV was low (20%). Further analyses indicated non-cirrhotic patients had a significantly lower 90-day transplantation‐free mortality and greater 5‐year survival rate than cirrhotic patients (59.5% vs. 27.6%, 62% vs. 36%, P<0.05). Age, hepatic encephalopathy, liver cirrhosis, nucleoside (acid) analogues (NAs) withdrawal, total bilirubin, and prothrombin time were independent risk factors for 90-day mortality in HBV-ACLF patients. Cirrhosis at admission (AOR=3.675, 95% CI: 2.408–6.594) was a strong independent risk factor for long-term prognosis. Conclusion: The proportion of HBV-ACLF patients receiving antiviral treatment was extremely low in south China. HBV combined with acute hepatitis E, or DILI had no significant effect on the short-term mortality rate in HBV-ACLF patients. Remarkably, the effect of withdrawal of NAs and cirrhosis on short-term outcomes cannot be ignored. No significant improvement in the short-term prognosis of HBV-ACLF patients was observed compared with previous studies. Trial Registration: The trial is registered at ClinicalTrials.gov (CT.gov identifier: NCT04231565). Registered 13 May 2020https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S0009OZY&selectaction=Edit&uid=U00036P1&ts=2&cx=27seqt


Author(s):  
Els LLM De Schryver ◽  
Ingrid Blom ◽  
Kees PJ Braun ◽  
L Jaap Kappelle ◽  
Gabriël JE Rinkel ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document